Literature DB >> 34428430

Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors.

Emmanuelle S Jecrois1, Wang Zheng2, Miriam Bornhorst3, Yinghua Li2, Daniel M Treisman2, Daphine Muguyo2, Sharon Huynh2, Shayne F Andrew2, Yuan Wang2, Jingwen Jiang2, Brianna R Pierce2, Hongmei Mao2, Matthew K Krause2, Austin Friend2, Francisco Nadal-Nicolas4, Steven F Stasheff5, Wei Li4, Hui Zong6, Roger J Packer7, Yuan Zhu8.   

Abstract

The mechanism of vulnerability to pediatric low-grade gliomas (pLGGs)-the most common brain tumor in children-during development remains largely unknown. Using mouse models of neurofibromatosis type 1 (NF1)-associated pLGGs in the optic pathway (NF1-OPG), we demonstrate that NF1-OPG arose from the vulnerability to the dependency of Mek-Erk/MAPK signaling during gliogenesis of one of the two developmentally transient precursor populations in the optic nerve, brain-derived migrating glial progenitors (GPs), but not local progenitors. Hyperactive Erk/MAPK signaling by Nf1 loss overproduced GPs by disrupting the balance between stem-cell maintenance and gliogenesis of hypothalamic ventricular zone radial glia (RG). Persistence of RG-like GPs initiated NF1-OPG, causing Bax-dependent apoptosis in retinal ganglion cells. Removal of three Mek1/Mek2 alleles or transient post-natal treatment with a low-dose MEK inhibitor normalized differentiation of Nf1-/- RG-like GPs, preventing NF1-OPG formation and neuronal degeneration. We provide the proof-of-concept evidence for preventing pLGGs before tumor-associated neurological damage enters an irreversible phase.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NF1; Neurofibromatosis type 1; hMZ-RG; hVZ-RG; hypothalamic mantle zone radial glia; hypothalamic ventricular zone radial glia; neural stem cells; optic pathway glioma (OPG); pediatric low-grade glioma; pilocytic astrocytoma

Mesh:

Year:  2021        PMID: 34428430     DOI: 10.1016/j.devcel.2021.08.004

Source DB:  PubMed          Journal:  Dev Cell        ISSN: 1534-5807            Impact factor:   12.270


  5 in total

1.  A therapeutic window for preventive therapy in NF1-associated optic pathway glioma.

Authors:  Yuan Zhu; Wang Zheng; Emmanuelle S Jecrois; Brianna R Pierce; Daniel M Treisman
Journal:  Mol Cell Oncol       Date:  2021-11-30

2.  Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.

Authors:  Ovais Shafi; Ghazia Siddiqui
Journal:  World J Surg Oncol       Date:  2022-05-10       Impact factor: 3.253

3.  SAPCD2 promotes neuroblastoma progression by altering the subcellular distribution of E2F7.

Authors:  Zi-Mu Zhang; Hai-Bo Cao; Zhi-Heng Li; Ran Zhuo; Yan-Fang Tao; Xiao-Lu Li; Gen Li; Xin-Mei Liao; Fang Fang; Yi Xie; Di Wu; Hai-Rong Wang; Jian-Wei Wang; Yan-Ling Chen; Juan-Juan Yu; Si-Qi Jia; Ran-Dong Yang; Xin-Yi Guo; Yang Yang; Chen-Xi Feng; Yun-Yun Xu; Guang-Hui Qian; Jian Pan
Journal:  Cell Death Dis       Date:  2022-02-23       Impact factor: 8.469

Review 4.  The RASopathies: from pathogenetics to therapeutics.

Authors:  Katie E Hebron; Edjay Ralph Hernandez; Marielle E Yohe
Journal:  Dis Model Mech       Date:  2022-02-18       Impact factor: 5.758

5.  Modulation of Sirt1-mTORC1 Pathway in Microglia Attenuates Retinal Ganglion Cell Loss After Optic Nerve Injury.

Authors:  Qianxue Mou; Ke Yao; Meng Ye; Bowen Zhao; Yuanyuan Hu; Xiaotong Lou; Huixia Li; Hong Zhang; Yin Zhao
Journal:  J Inflamm Res       Date:  2021-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.